December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Giuseppe Lombardi: Pleased to announce the academic MIRAGE trial for patients with recurrent grade 2-3 meningioma
Sep 24, 2024, 23:18

Giuseppe Lombardi: Pleased to announce the academic MIRAGE trial for patients with recurrent grade 2-3 meningioma

Giuseppe Lombardi, Head of the Neuro-Oncology Unit at the Veneto Institute of Oncology, shared a post on LinkedIn:

”I am pleased to announce the academic MIRAGE trial for patients with recurrent grade 2-3 meningioma. This is the first randomized trial to evaluate a tyrosine kinase inhibitor in meningioma.”

Giuseppe Lombardi

Source: Giuseppe Lombardi/LinkedIn

Giuseppe Lombardi is the Head of the Neuro-Oncology Unit at Veneto Oncology Institute IOV – IRCCS and Oncologist MD at Veneto Oncology Institute of Padua. Previously, he has been part of the neuro – oncology faculty at the Memorial Sloan Kettering Cancer Center.